Strongest gains in the SBF 120: Valneva stock rebounds 3.5%

A rebound that recovers only a small portion of the monthly decline

The Valneva stock gains 3.66% to €2.58 during trading, after declining 4.5% the previous day. It ranks among the strongest gainers in the SBF 120, while the index advances 0.85%. The move mitigates but does not offset the 13.35% decline recorded over one month, and the stock still shows a loss of 45.42% over one year.

The price remains below its three moving averages: the gap is 5.29% with the MA20 (€2.72) and 15.82% with the MA200 (€3.06). The support level at €2.50 is situated less than 3% from the current price, and the RSI at 38 remains neutral. The stock had broken through the €2.66 support level on October 1st, and the resistance at €2.99 remains the identified ceiling in the zone.

Ixchiq revoked across the Channel, S1 2026 activity in the background

Thursday's session was marked by the revocation of authorization for the Ixchiq vaccine against chikungunya by the United Kingdom, announced by the laboratory on October 7th. This decision followed a supplementary evaluation of the benefit-risk ratio for travelers, conducted by the British Commission on Human Medicines. Upon publication of S1 2026 on August 13, 2026, the company had confirmed its outlook for the year, while citing among risks the refocusing of Ixchiq on endemic markets.

It also highlighted anticipated regulatory decisions on its Lyme disease vaccine candidate within the following twelve months. Valneva is listed in Paris and, in the form of ADSs (1 ADS for 2 shares), on the Nasdaq, but Paris concentrates the bulk of trading volumes.